Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propagermanium crossover study in primary focal segmental glomerulosclerosis
ACTRN12618000910202Phase 2Completed
- Sponsor
- Dimerix
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of repagermanium in focal segmental glomerulosclerosis (FSGS) (2 arms), sponsored by Dimerix. Primary endpoint: Safety of adjunct propagermanium with irbesartan. Started Nov 2018; status: completed.
02
Drugs
repagermanium
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on ACTRN12618000910202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000910202.